So this nuisance lawsuit is costing Pfizer a percentage of revenue because Pfizer has to pay Purdue a portion of revenue made or a royalty because Pfizer was guilty of patent infringement stealing a part of Purdues IP for the single beaded ADT. Hardly a nuisance if any company gets a portion of ones revenue not matter what it is. Now lets say Elite comes in the picture. Losing market share is cumulative even if it means having to pay a royalty to a competitor because you stole their IP.
One more thing... this will also apply to Pfizers Oxy single beaded. PFE will have to pay a royalty on that one to Purdue too. Not a doubt. PFE is lucky that is all they have to pay Purdue for their discretion.
A few percent here and a few percent there all adds up to big percent lost.
News 
Market Data 
Discover 
